Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other financing activities (2016 - 2022)

Syndax Pharmaceuticals has reported Other financing activities over the past 8 years, most recently at $92000.0 for Q1 2022.

  • Quarterly results put Other financing activities at $92000.0 for Q1 2022, up 16.46% from a year ago — trailing twelve months through Mar 2022 was $13000.0 (down 18.75% YoY), and the annual figure for FY2020 was $1000.0, down 99.45%.
  • Other financing activities for Q1 2022 was $92000.0 at Syndax Pharmaceuticals, up from -$242000.0 in the prior quarter.
  • Over the last five years, Other financing activities for SNDX hit a ceiling of $99000.0 in Q3 2021 and a floor of -$242000.0 in Q4 2020.
  • Median Other financing activities over the past 5 years was $57000.0 (2019), compared with a mean of $24764.7.
  • Biggest five-year swings in Other financing activities: surged 3500.0% in 2018 and later plummeted 524.56% in 2020.
  • Syndax Pharmaceuticals' Other financing activities stood at $17000.0 in 2018, then soared by 235.29% to $57000.0 in 2019, then plummeted by 524.56% to -$242000.0 in 2020, then changed by 0.0% to -$242000.0 in 2021, then surged by 138.02% to $92000.0 in 2022.
  • The last three reported values for Other financing activities were $92000.0 (Q1 2022), -$242000.0 (Q4 2021), and $99000.0 (Q3 2021) per Business Quant data.